The use of a BsAb against both HER2 and FcαRI (namely anti-HER2 × FcαRI) efficiently eliminated breast carcinoma cells by neutrophil accumulation, unlike the equivalent FcγRI-directed BsAb (anti-HER2 × FcγRI) [182]. The gene discussed is ERBB2; the disease is breast carcinoma.